Evaluation of Antifungal Efficacy in an Optimized Animal Model of Trichophyton mentagrophytes-Dermatophytosis

Abstract Dermatophytoses are known to cause considerable discomfort, cosmetic prob-lems and financial loss that have been recognized as a significant health concern worldwide. Since currently available antifungal agents have limitations in their effi-cacy, new agents are being developed. This study was undertaken to optimize an in vivo model of experimental dermatophytosis for evaluation of the efficacy of anti-fungal compounds. Guinea pigs were infected with different inocula of T. menta-grophytes to establish dermatophytosis. The optimal conditions for dermatophyto-sis in guinea pigs were found to be an inoculum size of 1 × 107 fungal cells applied on abraded skin. After optimization, animals were treated with oral or topical for-mulations of terbinafine. The optimized guinea pig model was found to be highly reproducible, and useful in the primary screening and evaluation of the anti-der-matophytic efficacy of topical and oral formulations of antifungal agents.

[1]  M. Ghannoum,et al.  New developments in chemotherapy for non-invasive fungal infections , 2001, Expert opinion on investigational drugs.

[2]  H. Schuppe,et al.  Efficacy testing of antimycotic prophylactics in an animal model. , 2001, International journal of hygiene and environmental health.

[3]  M. Ghannoum,et al.  An evaluation of the in vitro activity of terbinafine. , 2000, Medical mycology.

[4]  H. Korting,et al.  The use of systemic antimycotics in dermatotherapy. , 2000, European journal of dermatology : EJD.

[5]  M. Ghannoum,et al.  Antifungal Susceptibility Testing of Dermatophytes: Establishing a Medium for Inducing Conidial Growth and Evaluation of Susceptibility of Clinical Isolates , 2000, Journal of Clinical Microbiology.

[6]  M. Ghannoum,et al.  Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. , 1999, Journal of the American Academy of Dermatology.

[7]  B. Piraccini,et al.  Relapses of Onychomycosis after Successful Treatment with Systemic Antifungals: A Three-Year Follow-Up , 1998, Dermatology.

[8]  J. Leyden,et al.  Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. , 1997, Journal of the American Academy of Dermatology.

[9]  L. Bakos,et al.  Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. , 1997, The Pediatric infectious disease journal.

[10]  R. Summerbell,et al.  The dermatophytes , 1995, Clinical microbiology reviews.

[11]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days , 1994, Clinical and experimental dermatology.

[12]  L. Millérioux,et al.  Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. , 1993, Acta dermato-venereologica.

[13]  N. Shear,et al.  Terbinafine: an oral and topical antifungal agent. , 1991, Clinics in dermatology.

[14]  T. Jones,et al.  Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses , 1989, Clinical and experimental dermatology.

[15]  I. Leitner,et al.  The "hair root invasion test", a semi-quantitative method for experimental evaluation of antimycotics in guinea-pigs. , 1982, Sabouraudia.